Kailyn A. Deitz

Kailyn A. Deitz

Auto-generated profile, based on publicly available information

Kailyn A. Deitz

Center for Predictive Medicine for Biodefense and Emerging Infectious diseases, University of Louisville, Louisville, KY 40202, USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 May 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
LALIT BATRALALIT BATRA
LALIT BATRA
Divyasha SaxenaDivyasha Saxena
Divyasha Saxena
TPTriparna Poddar
Triparna Poddar
MZMaryam Zahin
Maryam Zahin
AAAlok Amraotkar
Alok Amraotkar
KPKenneth E. Palmer
Kenneth E. Palmer
Background/Objectives: The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus type-2 (SARS-CoV-2), has resulted in 777 million cases worldwide. Various vaccines have been approved to control the spread of COVID-19, with mRNA vaccines (Pfizer and Moderna) being widely used in the USA. We conducted a prospective longitudinal study to analyze the immune response elicited by two/three and four doses of monovalent mRNA vaccines in both vaccinated individuals and those who experienced breakthrough infections. Participants were stratified into different age groups: 18–40, 41–60, and over 60 years. Methods: We assessed cross-variant neutralization responses in two cohorts—Cohort I: n = 167 (serum), Cohort II: n = 92 (serum and nasal swab) samples—using infectious virus microneutralization assay (MN) and antibody (IgG or IgA) binding ELISA titers to the spike protein receptor binding domain (RBD). Samples were collected from the Louisville Metro–Jefferson County Co-Immunity Project, a federally funded, population-based study for the surveillance of SARS-CoV-2 in Jefferson County, Kentucky during 2020–2022, involving both health care workers and a local community. Results: Individuals who received two doses of the mRNA vaccine exhibited reduced neutralization against Beta, Delta, and Omicron BA.1 variants compared to wildtype Wuhan, with further decline observed six months post-booster vaccination. However, individuals who experienced natural COVID-19 infection (breakthrough) after receiving two vaccine doses showed enhanced neutralization and antibody responses, particularly against Omicron BA.1. Following the 3rd dose, antibodies and neutralization responses were restored. Among triple-vaccinated individuals, reduced neutralization was observed against Omicron variants BA.1, BA.5, and BA.2 compared to Wuhan. Neutralization responses were better against BA.2 variant compared to BA.1 and BA.5. However, individuals who received three doses of vaccine and experienced a breakthrough infection (n = 45) elicited significantly higher neutralizing antibodies responses against all Omicron subvariants compared to vaccinated individuals. Interestingly, nasal swab samples collected from volunteers with breakthrough infection showed significantly elevated spike-reactive mucosal IgA antibodies and enhanced cross neutralization against BA.1, BA.2, and BA.5 compared to individuals who received only three vaccine doses. Conclusions: mRNA vaccination elicits a strong systemic immune response by boosting serum neutralizing antibodies (NAb), although this protection wanes over time, allowing new variants to escape neutralization. Breakthrough individuals have extra enrichment in nasal NAb offering protection against emerging variants. This longitudinal immune profiling underscores the strengthening of pandemic preparedness and supports the development of durable mucosal vaccines against respiratory infectious disease.

1 June 2025 in Journal of Anesthesia and Translational Medicine
Verified
Journal Article
Open access
YHYuchen Han
Yuchen Han
GLGrace A. Long
Grace A. Long
T'shura AliT'shura Ali
T'shura Ali
KDKailyn Deitz
Kailyn Deitz
HSHarideep Samanapally
Harideep Samanapally
JHJiapeng Huang
Jiapeng Huang
COVID-19 has had a significant impact on the scientific field. The multitude of effects this virus has on different organ systems is a continuously expanding range of study. The purpose of this study is to differentiate between the cardiac effects of the three different waves of COVID identified between March 2020- July 2022 using echocardiographic results and the cardiac biomarkers troponin and B-type natriuretic peptide (BNP). By using this information, we can evaluate cardiac impact from COVID-19, which may lead to effects on overall survival. Information was gathered through eight acute care facilities as part of a multi-center retrospective observational cohort study of patients hospitalized with confirmed SARS-CoV-2, who experienced a cardiovascular event and received an echocardiogram during admission between March 2020 and July 2022. A total of 222 participants were included and divided into 3 waves based on the highest SARS-CoV-2 strain prevalence at the time in Louisville, KY, USA. This consisted of 56 patients in the Original wave 1 (March–July 2020), 143 during the Delta wave 2 (September 2020–March 2021), and 23 during the Omicron wave 3 (January 2022-July 2022). There were statistically significant differences in cardiac functions as indicated by echocardiogram and cardiac biomarkers. The Original wave not only showed the highest intensive care unit (ICU) admission rate of 73.2 %, but it also had a notable left ventricular diastolic dysfunction and the highest BNP levels. The Delta wave had the highest troponin value of 3.1 ng/mL. The left atrial volume of patients in the Omicron wave was significantly lower than in the Original and Delta waves. However, the tricuspid annular place systolic excursion for patients in the Omicron wave was significantly higher than the other two waves. In survival time models correlated with echocardiograph parameters, the Original wave showed significant correlations between left ventricular ejection fraction, left ventricular volume, right ventricular diameter, and survival. Delta wave showed significant correlation between ascending aortic size, right ventricular systolic pressure, right atrial pressure, and survival. the Omicron wave displayed significant correlation between peak troponin levels and survival. COVID-19 variants showed statistically significant impacts on cardiac function and biomarkers. There were significant correaltions between these echocardiographic parameters and biomarkers with survival. These cardiac differences can be used to determine overall severity of disease and provide insight into the level of clinical care indicated in COVID patients.